Sumitomo Pharma Co Ltd (STU:DPM)
€ 3.5 0.02 (0.57%) Market Cap: 1.41 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 2.04 GF Score: 63/100

Sumitomo Dainippon Pharma Co Ltd R&D Meeting Transcript

Mar 03, 2020 / NTS GMT
Release Date Price: €12.9
Unidentified Participant

We'd like to begin. Thank you for joining the R&D meeting with Sumitomo Dainippon Pharma. Just for your information, this meeting is being broadcasted live and is telephonic. Today's presenters are Mr. Nomura, President and CEO of the company; Dr. Kimura, who will be presenting Psychiatry & Neurology area and Regenerative Medicine & Cell Therapy; Dr. Koshiya, who will be presenting Oncology area. And from the United States, we have Dr. Kenneth Koblan, Chief Scientific Officer in Sunovion Pharmaceuticals. I'm [Higuchi], a moderator.

We will be using the slide deck we sent out via e-mail. This is the agenda. Mr. Nomura will present the overview at the introduction, followed by the presentation on Psychiatry & Neurology area and then Regenerative Medicine & Cell Therapy by Dr. Kimura, followed by the presentation on Oncology area by Dr. Koshiya, followed by the presentation on SEP-363856 by Dr. Koblan. We will have a Q&A session at the end of the meeting. We can take questions from those who are joining on the phone.

Without further ado, I'd like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot